Novel oral anticoagulants in development: Dabigatran, rivaroxaban, and apixaban

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages 332-338

  Sattari, Maryam ^a,b   Lowenthal, David T ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

oral anticoagulants

Indexed keywords

AMIODARONE; APIXABAN; CLARITHROMYCIN; CYTOCHROME P450; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; ERYTHROMYCIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERICUM PERFORATUM; LIVER DYSFUNCTION; LIVER TOXICITY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; STROKE; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; AZETIDINES; BENZIMIDAZOLES; BENZYLAMINES; DRUG APPROVAL; HUMANS; MORPHOLINES; PULMONARY EMBOLISM; PYRAZOLES; PYRIDINES; PYRIDONES; THIOPHENES; UNITED STATES; VENOUS THROMBOSIS;

EID: 79960556525     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181da0773     Document Type: Review

References (63)

1. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractio-nated heparin and Warfarin: current and future advances. Circulation. 2007;116:552-560. (Pubitemid 47450264)
2. Warwick D, Friedman RJ, Angelli G, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008;24:87-97. (Pubitemid 351160242)
3. Nieuwlaat R, Capucci A, Lip GY, et al. Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2006;27:3018-3026. (Pubitemid 44963431)
4. Glazwer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246-252.
5. Laux V, Persborn E, Heitmeier S. Direct inhibitors of coagulation protetins\-the end of heparin and low-molecular-weight heparin era for anticoagulation therapy? Thromb Haemost. 2009;102:892-899.
6. Erikkson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007: 2178-2185. (Pubitemid 47617868)
7. Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370:949-956. (Pubitemid 47393577)
8. Ginsberg JS, Davidson BL, Comp PC, et al; RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabiga-tran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
9. Kakker AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short term enoxaparin for the pre-vention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008;372:31-39.
10. Lassen MR, Ageno W, Boris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2009;358:2776-2786. (Pubitemid 351930852)
11. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement arthroplasty (RECORD 4): a random-ized trial. Lancet. 2009;373:1673-1680.
12. Eriksson BI, Boris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for throm-boprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358:2765-2786.
13. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replace-ment. N Engl J Med. 2009;361:594-604.
14. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;45:914-918. (Pubitemid 351301746)
15. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-1040. (Pubitemid 41262337)
16. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboem-bolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med. 2001;161:2215-2221. (Pubitemid 32905002)
17. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelaga-tran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A random-ized, double-blind trial. Ann Intern Med. 2002;37:648-655. (Pubitemid 35176097)
18. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721. (Pubitemid 37315008)
19. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002;360:1441-1447. (Pubitemid 35356320)
20. Shapiro SS. Treating thrombosis in the 21st century. N Engl J Med. 2003;349:1762-1764. (Pubitemid 37315014)
21. Gurewich V. Ximelagatran\-promises and concerns. JAMA. 2005;293:736-739.
22. Kaul S, Diamond GA, Weintraub WS. Trials and tribula-tions of non-inferiority the ximelagatran experience. J Am Coll Cardiol. 2005;46:1986-1995. (Pubitemid 41713579)
23. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186-195. (Pubitemid 351712643)
24. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. (Pubitemid 40562946)
25. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155-162. (Pubitemid 47078782)
26. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757-1766. (Pubitemid 34415371)
27. Van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin. Blood. 2007;110.
28. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133:234-256.
29. Stangier J, Rathgen K, Stahle H, et al. The pharmacoki-netics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. (Pubitemid 47283865)
30. European Medicines Agency (EMEA). European Public Assessment Report\-Pradaxa. Available at: http://www. emea.europa.edu/humandocs/PDFs/EPAR/ pradaxa/ H-829-en6.pdf. Accessed December 2009.
31. DuBuske LM. The role of p-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf. 2005;28:789-801. (Pubitemid 41428552)
32. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthro-plasty. A meta-analysis. Thromb Haemost. 2009;101:77-85.
33. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal prod-ucts in non-surgical patients. J Thromb Haemost. 2005;3: 692-694. (Pubitemid 41647882)
34. Schulman S, Kearon C, Kakker AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al, the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY, NCT00262600). N Engl J Med. 2009;361:1139-1151.
36. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100: 1419-1426. (Pubitemid 47576022)
37. Bauer KA. New anticoagulants: anti IIa vs anti Xa-is one better?J Thromb Thrombolysis. 2006;21:67-72. (Pubitemid 43231131)
38. Ansell J. Factor Xa vs. thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(Suppl 1):60-64.
39. Kubitza D, Becka M, Wensing G, et al. Safety, pharma-codynamics, and pharmacokinetics of BAY 59-7939\-an oral, direct Factor Xa inhibitor\-after multiple dosing in healthy male subjects. Eur J CLin Pharmacol. 2005;61: 873-880. (Pubitemid 41803696)
40. Mueck W, Eriksson BI, Bauer KA, et al. Population phar-macokinetics and pharmacodynamics of rivaroxaban\- an oral direct factor Xa inhibitor in patients undergoing major orthopedic surgery. Clin Pharmacokinet. 2008;47: 203-216.
41. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.
42. Borris LC. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag. 2008;4:855-864
43. EMEA CHMP Assessment Report for Xarelto. Available at: http://www.emea.europa.edu/humandocs/PDFs/ EPAR/xarlelto/H-944-en6.pdf. Accessed December 2009.
44. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and p-glycoprotein. Fund Clin Pharmacol. 2004;18:621-626. (Pubitemid 39564261)
45. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorp-tion and BAY 59-7939 (rivaroxaban), an oral direct Xa inhibitor, in health subjects. J Clin Pharmacol. 2006;46: 549-558.
46. Mueck W, Eriksson BI, Bauer KA, et al. Population phar-macokinetics and pharmacodynamics of rivaroxaban\- an oral direct factor Xa inhibitor\-in patients undergoing major orthopedic surgery. Clin Pharmacokinet. 2008;47: 203-216.
47. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban\-an oral, direct factor Xa inhibitor has potential for the management of patients with heparin-induced thrombo-cytopenia. Br J Haematol. 2008;143:92-99.
48. Haas S. Rivaroxaban\-an oral, direct Factor xa inhibitor: lessons from a borad clinical study programme. Eur J Haematol. 2009;82:339-349.
49. Buller HR, Agnelli G, Cohen A, et al. Einstein-DVT Dose-Ranging Study Inverstigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242-2247.
50. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-187. (Pubitemid 47057524)
51. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29-38.
52. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration in hu-mans. Drug Metab Dispos. 2009;37:74-81.
53. Wong PC, Crain EJ, Xin RR, et al. Apixaban, an oral direct and highly selective factor Xa inhibitor: in vitro, antith-rombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820-829. (Pubitemid 351524543)
54. Harennberg J, Wehling M. Current and future prospects for anticoagulation therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008;34:39-57. (Pubitemid 351640881)
55. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharma-codynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
56. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368-2375. (Pubitemid 350154345)
57. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-1318. (Pubitemid 352016310)
58. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the 59. Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877.
59. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008;28:380-386.
60. Kessler CM. Current and future challenges of antithrom-botic agents and anticoagulants: Strategies for reversal of hemorrhagic complications. Semin Hematol. 2004;41:44.
61. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesthesiol. 2002;49:S11-S25.
62. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients un-dergoing anticoagulant therapy: focus on new anticoag-ulant agents. Blood. 2008;111:4871-4879.
63. Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res. 2008;123:52-56.